摘要
目的系统评价银杏叶制剂治疗出血性中风急性期的临床疗效及安全性。方法运用系统评价方法,检索银杏叶制剂治疗中风的随机对照试验,筛选合格研究,评价研究质量,采用异质性检验、Meta分析、敏感性分析、倒漏斗图等方法统计相关数据。结果 5项研究符合选择标准,试验措施均为银杏叶注射液,其治疗出血性中风急性期总有效率比较的RR(99%CI)、神经功能缺损评分、脑血肿体积变化比较的WMD(99%CI)统计结果依次为1.40(0.96,2.03)、-7.47(-9.98,-4.96)、-9.72(-13.73,-5.70)。结论现有证据显示银杏叶注射液有益于改善出血性中风急性期患者的神经功能缺损及脑血肿状况,且安全性较高。
Objective： To evaluate efficacy and safety of the ginkgo biloba extract on acute phase of hemorrhagic stroke.Methods： Randomized controlled trails（RCTs） of ginkgo biloba extract for acute phase of hemorrhagic stroke were identified,eligible studies were included.The methodological quality of inclusive trails was assessed by Jadad scale.Heterogeneity test,Meta-analysis,funnel plot analysis and sensitivity analysis were used to analyse data.Results： 5 studies were collected.The meta-analysis indicated that the RR（99%CI） of the total effective rate,the WMD（99%CI） of the neural function defect score and the cephalophyma volume change was 1.40（0.96,2.03）,-7.47（-9.98,-4.96）,-9.72（-13.73,-5.70）.Conclusion： This systematic review shows that the ginkgo biloba extract can improve the neural function and the cephalophyma.It is safety that this drug was used in the acute phase of hemorrhagic stroke.
出处
《中国中医急症》
2013年第6期869-871,共3页
Journal of Emergency in Traditional Chinese Medicine
基金
国家自然科学基金资助课题(30801458)
关键词
银杏叶
出血性中风急性期
系统评价
随机对照试验
Ginkgo biloba
Acute phase of hemorrhagic stroke
Systematic review
Randomized controlled trail
